Director at Lucid Diagnostics (NASDAQ: LUCD) receives 123,000-share restricted stock grant

Rhea-AI Filing Summary

Lucid Diagnostics Inc. director James L. Cox reported an equity award of common stock. He acquired 123,000 shares of restricted stock at a grant price of $0.00 per share as a grant, award, or other acquisition under the company’s 2018 Equity Plan. These restricted shares have a single vesting date of May 20, 2029 and are subject to forfeiture if the required service period is not completed. Following this award, Cox directly holds a total of 405,120 shares of Lucid Diagnostics common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Cox James L

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	123,000	$0.00	--

Holdings After Transaction: Common Stock — 405,120 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cox James L

(Last) (First) (Middle)

360 MADISON AVENUE

25TH FLOOR

(Street)

NEW YORK NY 10017

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lucid Diagnostics Inc. [ LUCD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/20/2026		A		123,000(1)	A	$0	405,120	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed

	/s/ Michael A. Gordon, by power of attorney	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Lucid Diagnostics (LUCD) director James L. Cox report?

James L. Cox reported receiving 123,000 shares of Lucid Diagnostics common stock as a restricted stock grant. The award was made under the company’s 2018 Equity Plan at a grant price of $0.00 per share and represents a non-cash equity compensation grant.

When do James L. Cox’s Lucid Diagnostics (LUCD) restricted shares vest?

The 123,000 restricted shares granted to James L. Cox have a single vesting date of May 20, 2029. The shares are subject to forfeiture if he does not complete the requisite service period, linking the award to long-term service with Lucid Diagnostics.

How many Lucid Diagnostics (LUCD) shares does James L. Cox own after this Form 4 grant?

After the reported restricted stock grant, James L. Cox directly holds 405,120 shares of Lucid Diagnostics common stock. This total includes the newly awarded 123,000 restricted shares, which are subject to vesting conditions and potential forfeiture if service requirements are not met.

What is the transaction code and nature of James L. Cox’s LUCD Form 4 transaction?

The transaction is coded “A” on Form 4, indicating a grant, award, or other acquisition. It reflects a non-derivative restricted stock award of 123,000 Lucid Diagnostics common shares, received as equity compensation rather than an open-market purchase or sale.

Under which plan was the Lucid Diagnostics (LUCD) restricted stock granted to James L. Cox?

The 123,000 restricted shares were granted under Lucid Diagnostics’ 2018 Equity Plan. This plan provides for equity-based compensation, and the awarded restricted stock carries a single vesting date of May 20, 2029, contingent on completion of a specified service period.